share_log

MoneyGram Partners Ebix to Offer Inward Remittance in India

MoneyGram Partners Ebix to Offer Inward Remittance in India

速匯金合作伙伴Ebix將在印度提供匯款服務
Zacks Equity Research ·  2020/01/14 00:00

MoneyGram International, Inc. (MGI-Free Report) has tied up with Ebix, Inc. , a leading international supplier of On-Demand software and e-commerce services.

速匯金國際公司(MGI-自由報告)已與Ebix,Inc.是一家領先的國際點播軟件和電子商務服務供應商。

Per the agreement, Ebix’s wholly-owned subsidiary, EbixCash will be the exclusive partner of MoneyGram in India. Its customers will be able to reach out to MoneyGram to seamlessly receive money from family and friends around the world.

根據協議,Ebix的全資子公司EbixCash將成為速匯金在印度的獨家合作伙伴。它的客户將能夠聯繫速匯金,無縫地從世界各地的家人和朋友那裏收到錢。

Ebix’s huge presence in India makes it a perfect fit for MoneyGram. Ebix has 320,000 distribution outlets spread across 768 districts, 4,000 cities, and more than 75,000 villages, giving it a significant presence in rural India.

Ebix在印度的巨大影響力使其非常適合速匯金。Ebix在768個地區、4,000個城市和75,000多個村莊擁有32萬個分銷網點,使其在印度農村地區佔有重要地位。

Per the deal, MoneyGram will be handling inward remittances to India. The country is expected to see inward remittances of $3 billion annually. This makes India the leading remittance-receiving country in Asia and an attractive market for MoneyGram.

根據協議,速匯金將處理向印度的匯入匯款。預計該國每年的入境匯款將達到30億美元。這使得印度成為亞洲主要的匯款接收國,也是速匯金的一個有吸引力的市場。

This move also reflects MoneyGram’s strategy to expand its international operations at a time when revenue growth in the United States is difficult to achieve, given intense competition from new fintech players such as TransferWise, Azimo, Remitly and WorldRemit, to name a few.

此舉也反映出速匯金在美國營收增長難以實現的情況下擴大國際業務的戰略,考慮到來自TransferWise、Azimo、Remitly和WorldRemit等金融科技新玩家的激烈競爭,僅舉幾例。

These companies utilize online and mobile platforms to transfer money, which makes their services more cost-effective and efficient. Unlike MoneyGram, which has to pay a commission to brick-and-mortar agents that originate the transfers, most of the players steer clear of the same, because of their use of digital channels. This helps them save a large chunk of operating cost and enables them to enjoy better operating margins.

這些公司利用在線和移動平台轉賬,這使得他們的服務更具成本效益和效率。與速匯金不同的是,速匯金必須向發起轉賬的實體代理商支付佣金,而大多數玩家都避免這樣做,因為他們使用的是數字渠道。這幫助他們節省了一大筆運營成本,並使他們能夠享受更高的運營利潤率。

It is to be noted that revenues from MoneyGram’s U.S. operations declined by 1.4% and 13% in 2017 and 2018, respectively. Over the past two years, its market capitalization has eroded by nearly 72%.

需要指出的是,2017年和2018年,速匯金美國業務的收入分別下降了1.4%和13%。在過去的兩年裏,它的市值縮水了近72%。

The stock has lost 8.5% against the industry’s growth of 16.5% in the past year. This performance pales in comparison with the price gains of 5.3% for Square, 51.4% for Western Union Co. (WU-Free Report) and 27.5% for PayPal Holdings, Inc. (PYPL-Free Report) .

與過去一年該行業16.5%的增長相比,該股下跌了8.5%。這一表現與Square公司5.3%的價格漲幅、西聯匯款公司51.4%的價格漲幅和西聯匯款公司27.5%的價格漲幅相比相形見絀。貝寶控股,Inc.(PYPL-Free Report)。

20200114193856247d246shkds0kmkhg

MoneyGram is making continuous investments to develop its digital platforms. Notably, the company witnessed a record-breaking online transaction growth during the most recent holiday shopping season.

速匯金正在不斷進行投資,以開發其數字平台。值得注意的是,在最近的假日購物季,該公司見證了創紀錄的在線交易增長。

MoneyGram carries a Zacks Rank #3 (Hold).

速匯金的排名是Zacks#3(持有)。

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

你可以看到這裏是今天ZACKS排名第一(強力買入)股票的完整名單.

Breakout Biotech Stocks with Triple-Digit Profit Potential

生物科技股突破三位數盈利潛力

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

隨着科學家開發數千種疾病的治療方法,預計到2024年,生物技術行業的規模將超過7750億美元。他們還在想方設法編輯從字面上消除我們對這些疾病的脆弱性。

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

扎克斯剛剛發佈了《生物世紀:7只生物科技股買對了》(Century of Biology:7只生物科技股買對了現在幫助投資者從7只有望跑贏大盤的股票中獲利。我們最近的生物技術建議在短短兩個月內產生了+50%、+83%和+164%的收益。這份報告中的股票可能表現得更好。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論